Cortexyme’s $76 Million Series B Financing

Orrick has advised Cortexyme on the deal

Cortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, completed a $76 million Series B financing. New investors include Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, and one of the world’s largest long-term mutual funds. All of Cortexyme’s current investors participated, including Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures, and Dolby Family Ventures.

Cortexyme also announced the successful completion of a placebo-controlled single ascending dose trial and a multiple ascending dose trial in healthy older volunteers of COR388, the company’s lead small molecule. COR388 was found to be safe and well tolerated by healthy volunteers ranging in age from 20-70 years old, producing a favorable pharmacokinetic profile and tissue distribution when given orally in a wide range of doses. Based on these encouraging results, the company is planning to start a phase 2 proof of efficacy study in AD patients next year.

The Orrick team was led by Tech Companies Group partner Scott Iyama (Picture) and included associates Laura Larsen and Brigid McCurdy.

Involved fees earner: Scott Iyama – Orrick;

Law Firms: Orrick;

Clients: Cortexyme Inc.;


Author: Ambrogio Visconti